FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 December 31. Expires: 2014

Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar		2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC [ NBIX									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)									
GORMAN KEVIN CHARLES															Directo			10% Ov		
							1									officer (give title elow)		Other (s	specify	
(Last) (First) (Middle)							3. Date of Earliest Transaction (Month/Day/Year) 05/22/2003										t Bus	iness Dev	.	
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
															_	filed by One Reporting Person				
(City) (State) (Zip)															Form filed by More than One Reporting Person				rting	
		Tab	le I - Nor	ı-Deriv	ativ	e Se	curities	Acc	quired, I	Disp	osed o	f, or B	enef	icially	y Owned	l				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						ear)   i	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Code (Instr.			4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) (D)	or 1	Price	Reported Transact (Instr. 3	tion(s)			(Instr. 4)		
Common Stock 05/22/						/2003			A		2,000			48.51	29	29,497		D		
		-	Table II -						uired, Di , option:						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, T	1. Fransa Code (1 3)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisabl		xpiration vate	Title	or Nu of	nount mber ares						
Statutory	49.51	05/22/2003			_		40,000		06/22/2003		5/22/2013	Common	40	000	\$40.51	186.65		D		

## **Explanation of Responses:**

Option<sup>(1)</sup>

1. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on June 22, 2003 an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

> Margraet E. Valeur-Jensen 05/27/2003

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.